Cathepsin K regulates localization and secretion of Tartrate-Resistant Acid Phosphatase (TRAP) in TRAP-overexpressing MDA-MB-231 breast cancer cells

[1]  T. Lundbäck,et al.  Identification of inhibitors of Tartrate‐resistant acid phosphatase (TRAP/ACP5) activity by small‐molecule screening , 2018, Chemical biology & drug design.

[2]  Yu-Jin Dong,et al.  Prognostic significance of ACP5 expression in patients with lung adenocarcinoma , 2018, The clinical respiratory journal.

[3]  R. Branca,et al.  Tartrate-resistant acid phosphatase (TRAP/ACP5) promotes metastasis-related properties via TGFβ2/TβR and CD44 in MDA-MB-231 breast cancer cells , 2017, BMC Cancer.

[4]  D. Brömme,et al.  Cathepsin K osteoporosis trials, pycnodysostosis and mouse deficiency models: Commonalities and differences , 2016, Expert opinion on drug discovery.

[5]  M. Frank,et al.  The small chemical enzyme inhibitor 5-phenylnicotinic acid/CD13 inhibits cell migration and invasion of tartrate-resistant acid phosphatase/ACP5-overexpressing MDA-MB-231 breast cancer cells. , 2015, Experimental cell research.

[6]  P. Lång,et al.  The growth factor-like adipokine tartrate-resistant acid phosphatase 5a interacts with the rod G3 domain of adipocyte-produced nidogen-2. , 2014, Biochemical and biophysical research communications.

[7]  L. Duong,et al.  Inhibition of bone resorption by the cathepsin K inhibitor odanacatib is fully reversible. , 2014, Bone.

[8]  L. Duong,et al.  Efficacy of a Cathepsin K Inhibitor in a Preclinical Model for Prevention and Treatment of Breast Cancer Bone Metastasis , 2014, Molecular Cancer Therapeutics.

[9]  Y. Toiyama,et al.  Clinical significance of tartrate-resistant acid phosphatase type-5 expression in human gastric cancer. , 2014, Anticancer research.

[10]  Y. Nie,et al.  ACP5, a direct transcriptional target of FoxM1, promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma , 2014, Oncogene.

[11]  R. Baron,et al.  Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. , 2013, The Journal of clinical investigation.

[12]  A. Sahu,et al.  Dissection of Functional Sites in Herpesvirus Saimiri Complement Control Protein Homolog , 2012, Journal of Virology.

[13]  L. Duong,et al.  The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking. , 2011, Bone.

[14]  M. Platt,et al.  Multiplex Zymography Captures Stage-specific Activity Profiles of Cathepsins K, L, and S in Human Breast, Lung, and Cervical Cancer , 2011, Journal of Translational Medicine.

[15]  Gerald C. Chu,et al.  Proinvasion metastasis drivers in early-stage melanoma are oncogenes. , 2011, Cancer cell.

[16]  A. Jensen,et al.  The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial. , 2010, Clinical breast cancer.

[17]  G. Andersson,et al.  Biogenesis of tartrate-resistant acid phosphatase isoforms 5a and 5b in stably transfected MDA-MB-231 breast cancer epithelial cells. , 2010, Biochimica et biophysica acta.

[18]  Jun Yao,et al.  Epithelial and Stromal Cathepsin K and CXCL14 Expression in Breast Tumor Progression , 2008, Clinical Cancer Research.

[19]  R. Kiviranta,et al.  Proteolytic processing and polarized secretion of tartrate-resistant acid phosphatase is altered in a subpopulation of metaphyseal osteoclasts in cathepsin K-deficient mice. , 2007, Bone.

[20]  M. Warburton,et al.  Human breast cancer cell lines and tissues express tartrate‐resistant acid phosphatase (TRAP) , 2007, Cell biology international.

[21]  M. Krockenberger,et al.  Increased tartrate-resistant acid phosphatase (TRAP) expression in malignant breast, ovarian and melanoma tissue: an investigational study , 2006, BMC Cancer.

[22]  W. Seeger,et al.  Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration , 2005, Respiratory research.

[23]  K. Hultenby,et al.  Proteolytic Excision of a Repressive Loop Domain in Tartrate-resistant Acid Phosphatase by Cathepsin K in Osteoclasts* , 2005, Journal of Biological Chemistry.

[24]  N. Sträter,et al.  Crystal structures of recombinant human purple Acid phosphatase with and without an inhibitory conformation of the repression loop. , 2005, Journal of molecular biology.

[25]  E. G. Funhoff,et al.  Substrate positioning by His92 is important in catalysis by purple acid phosphatase , 2005, The FEBS journal.

[26]  N. Katunuma,et al.  Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells. , 2005, The journal of medical investigation : JMI.

[27]  Jyh‐cherng Yu,et al.  Tartrate-resistant acid phosphatase 5b is a useful serum marker for extensive bone metastasis in breast cancer patients. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  T. Chao,et al.  Tartrate-resistant acid phosphatase 5b as a serum marker of bone metastasis in breast cancer patients. , 2004 .

[29]  V. E. Goldberg,et al.  Tartrate-Resistant Acid Phosphatase as a Marker of Bone Metastases in Patients with Breast Cancer and Prostate Cancer , 2004, Bulletin of Experimental Biology and Medicine.

[30]  D. Hume,et al.  Phosphotyrosyl peptides and analogues as substrates and inhibitors of purple acid phosphatases. , 2004, Archives of biochemistry and biophysics.

[31]  K. Hollberg,et al.  TRACP as an Osteopontin Phosphatase , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[32]  J. Goldman,et al.  Tartrate‐resistant acid phosphatase isoform 5b: A novel serum marker for monitoring bone disease in multiple myeloma , 2003, International journal of cancer.

[33]  H. Caffier,et al.  Evaluation of tartrate-resistant acid phosphatase (TRAP) 5b as serum marker of bone metastases in human breast cancer. , 2003, Anticancer research.

[34]  R. Thomas,et al.  Cathepsin K mRNA and Protein Expression in Prostate Cancer Progression , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[35]  K. Hultenby,et al.  Osteoclasts from mice deficient in tartrate-resistant acid phosphatase have altered ruffled borders and disturbed intracellular vesicular transport. , 2002, Experimental cell research.

[36]  Sheila J. Jones,et al.  Overlapping functions of lysosomal acid phosphatase (LAP) and tartrate-resistant acid phosphatase (Acp5) revealed by doubly deficient mice. , 2001, Development.

[37]  E. G. Funhoff,et al.  Mutational analysis of the interaction between active site residues and the loop region in mammalian purple acid phosphatases. , 2001, Biochemistry.

[38]  M. Y. Lee,et al.  Heparin column analysis of serum type 5 tartrate-resistant acid phosphatase isoforms. , 2001, Journal of chromatography. B, Biomedical sciences and applications.

[39]  Jozef Van Beeumen,et al.  The Highly Exposed Loop Region in Mammalian Purple Acid Phosphatase Controls the Catalytic Activity , 2001, Chembiochem : a European journal of chemical biology.

[40]  I. James,et al.  Biosynthesis and processing of cathepsin K in cultured human osteoclasts. , 2001, Bone.

[41]  D. Hume,et al.  Structure, function, and regulation of tartrate-resistant acid phosphatase. , 2000, Bone.

[42]  G. Andersson,et al.  Tartrate-resistant purple acid phosphatase is synthesized as a latent proenzyme and activated by cysteine proteinases. , 1999, The Biochemical journal.

[43]  Sheila J. Jones,et al.  Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[44]  K. Kanaoka,et al.  Fluorescence microscopic demonstration of cathepsin K activity as the major lysosomal cysteine proteinase in osteoclasts. , 1998, Journal of biochemistry.

[45]  J. Sloane,et al.  The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. , 1997, Cancer research.

[46]  G. Andersson,et al.  Comparative studies of rat recombinant purple acid phosphatase and bone tartrate-resistant acid phosphatase. , 1997, The Biochemical journal.

[47]  C. Debouck,et al.  Cathepsin K, but Not Cathepsins B, L, or S, Is Abundantly Expressed in Human Osteoclasts (*) , 1996, The Journal of Biological Chemistry.

[48]  D. Mcnulty,et al.  Proteolytic Activity of Human Osteoclast Cathepsin K , 1996, The Journal of Biological Chemistry.

[49]  G. Andersson,et al.  The tartrate-resistant purple acid phosphatase of bone osteoclasts--a protein phosphatase with multivalent substrate specificity and regulation. , 1995, Acta orthopaedica Scandinavica. Supplementum.

[50]  R. Glew,et al.  Substrate specificity of Gaucher spleen phosphoprotein phosphatase. , 1981, Archives of biochemistry and biophysics.

[51]  F. Guo,et al.  Overexpressed ACP5 has prognostic value in colorectal cancer and promotes cell proliferation and tumorigenesis via FAK/PI3K/AKT signaling pathway. , 2019, American journal of cancer research.

[52]  N. Kushlinskii,et al.  Tartrate-resistant acid phosphatase as a marker of bone metastases in patients with breast cancer and prostate cancer , 2007, Bulletin of Experimental Biology and Medicine.

[53]  G. Andersson.  Research Article Differential expression of monomeric and proteolytically processed forms of tartrate-resistant acid phosphatase in rat tissues , 2005 .

[54]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[55]  M. Halushka,et al.  Concise Report , 2022 .